Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M709046200 on November 28, 2007

J. Biol. Chem., Vol. 283, Issue 4, 2002-2009, January 25, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/4/2002    most recent
M709046200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lito, P.
Right arrow Articles by McCormick, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lito, P.
Right arrow Articles by McCormick, J. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Evidence That Sprouty 2 Is Necessary for Sarcoma Formation by H-Ras Oncogene-transformed Human Fibroblasts*

Piro Lito, Bryan D. Mets, Susanne Kleff, Sandra O'Reilly, Veronica M. Maher, and J. Justin McCormick1

From the Carcinogenesis Laboratory, Department of Microbiology & Molecular Genetics and Department of Biochemistry & Molecular Biology, Michigan State University, East Lansing, Michigan 48824-1302

Sprouty 2 (Spry2) acts as an inhibitor of receptor tyrosine kinase signaling in various cellular contexts. Interestingly, Spry2 also prevents the c-Cbl-induced degradation of epidermal growth factor receptor (EGFR). We compared human fibroblasts malignantly transformed by overexpression of H-RasV12 oncogene to their nontransformed parental cells and found that the malignant cells express a high level of Spry2. These cells also exhibited an increase in the level of EGFR compared with their precursor cells. We found that intact EGFR was required if H-Ras-transformed cells were to grow in the absence of exogenous growth factors or form large colonies in agarose. When we decreased expression of Spry2, using a Spry2-specific shRNA, the H-RasV12-transformed fibroblasts could no longer form large colonies in agarose, grow in reduced levels of serum, or form tumors in athymic mice. The level of active H-Ras in these cells remained unaltered. A similar, but less pronounced, effect in tumor formation was observed when Spry2 was down-regulated in human patient-derived fibrosarcoma cell lines. In H-Ras-transformed cells Spry2 sustained the level and the downstream signaling activity of EGFR. In the parental, non-H-Ras-transformed fibroblasts, expression of Spry2 resulted in the inhibition of H-Ras and ERK activation, suggesting that the positive effect of Spry2 in tumor formation is specific to H-Ras transformation. Co-immunoprecipitation studies with H-Ras-transformed cells revealed that Spry2 and H-Ras interact and that H-Ras interacts with Spry2-binding partners, c-Cbl and CIN85, in a Spry2-dependent manner. These data show that Spry2 plays a critical role in the ability of H-Ras-transformed cells to form tumors in athymic mice.


Received for publication, November 5, 2007 , and in revised form, November 28, 2007.

* This work was supported by the Department of Health and Human Services from the National Institutes of Health Grant CA098305 (to J. J. M.) and by a Research Assistantship (to P. L.) from Michigan State University, College of Human Medicine.

1 To whom correspondence should be addressed: Carcinogenesis Laboratory, Food Safety and Toxicology Bldg., Michigan State University, East Lansing, MI 48824-1302. Tel.: 517-353-7785; Fax: 517-353-9004.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
A. Swat, I. Dolado, J. M. Rojas, and A. R. Nebreda
Cell Density-Dependent Inhibition of Epidermal Growth Factor Receptor Signaling by p38{alpha} Mitogen-Activated Protein Kinase via Sprouty2 Downregulation
Mol. Cell. Biol., June 15, 2009; 29(12): 3332 - 3343.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. J. Frank, D. W. Dawson, S. J. Bensinger, J. S. Hong, W. M. Knosp, L. Xu, C. E. Balatoni, E. L. Allen, R. R. Shen, D. Bar-Sagi, et al.
Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas
Blood, March 12, 2009; 113(11): 2478 - 2487.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Lito, B. D. Mets, D. M. Appledorn, V. M. Maher, and J. J. McCormick
Sprouty 2 Regulates DNA Damage-induced Apoptosis in Ras-transformed Human Fibroblasts
J. Biol. Chem., January 9, 2009; 284(2): 848 - 854.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement